PT  - JOURNAL ARTICLE
AU  - Zeybel, Mujdat
AU  - Altay, Ozlem
AU  - Arif, Muhammad
AU  - Li, Xiangyu
AU  - Yang, Hong
AU  - Fredolini, Claudia
AU  - Akyildiz, Murat
AU  - Saglam, Burcin
AU  - Gonenli, Mehmet Gokhan
AU  - Ural, Dilek
AU  - Kim, Woonghee
AU  - Schwenk, Jochen M.
AU  - Zhang, Cheng
AU  - Shoaie, Saeed
AU  - Nielsen, Jens
AU  - Uhlén, Mathias
AU  - Borén, Jan
AU  - Mardinoglu, Adil
TI  - Combined Metabolic Activators Reduces Liver Fat in Nonalcoholic Fatty Liver Disease Patients
AID  - 10.1101/2021.05.20.21257480
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.20.21257480
4099  - http://medrxiv.org/content/early/2021/05/23/2021.05.20.21257480.short
4100  - http://medrxiv.org/content/early/2021/05/23/2021.05.20.21257480.full
AB  - Nonalcoholic fatty liver disease (NAFLD) refers to excess fat accumulation in the liver. In animal experiments and human kinetic study, we found that administration of combined metabolic activators (CMA) promotes the oxidation of fat, attenuates the resulting oxidative stress, activates mitochondria and eventually removes excess fat from the liver. Here, we tested the safety and efficacy of CMA in NAFLD patients in a placebo-controlled 10-week study. We found that CMA significantly decreased hepatic steatosis and levels of aspartate aminotransferase, alanine aminotransferase, uric acid, and creatinine, whereas found no differences on these variables in the placebo group after adjustment for weight loss. By integrating clinical data with plasma metabolomics and inflammatory proteomics as well as oral and gut metagenomics data, we revealed the underlying molecular mechanisms associated with the reduced hepatic fat and inflammation in NAFLD patients and identified the key players involved in the host-microbiome interactions. In conclusion, we observed that CMA can be used develop a pharmacological treatment strategy in NAFLD patients.Competing Interest StatementAM, JB and MU are the founder and shareholders of ScandiBio Therapeutics and ScandiEdge Therapeutics. The other authors declare no conflict of interest.Clinical TrialNCT04330326Funding StatementThis work was financially supported by ScandiBio Therapeutics and Knut and Alice Wallenberg Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee at Koc University (Decision No: 2018.351.IRB1.043).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data associated with this study are available in the main text or the supplementary materials.